Friday 6 November 2026 Export VRDN’s income statement to Excel — free account

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.

Revenue: −63.5%
EPS: −5.00%
Free cash flow: −9.92%
Total debt: +1,064.9%

Quarter to September 2026, against a year earlier

Insider buying

28.50 0.05 −0.18%

Follow VRDN

Alert me

Market cap: $3.2B
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 3/9
Altman Z: 6.69
Beneish M: n/a
Dividend safety: n/a

Overview

Viridian Therapeutics, Inc. (VRDN) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Viridian Therapeutics, Inc. (VRDN) trades at a P/B ratio of 5.5×. Over the past ten years it has ranged from 0.0× (September 2021) to 18.4× (August 2022); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VRDN/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Viridian Therapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VRDN/metrics/pb-ratio">Viridian Therapeutics, Inc. (VRDN) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	4.5×	65.90%
FY2024	2.7×	(36.53%)
FY2023	4.2×	17.47%
FY2022	3.6×	(17.32%)
FY2021	4.4×	—
FY2020	0.0×	—
FY2019	1.0×	(45.37%)
FY2018	1.7×	(66.09%)
FY2017	5.2×	—
FY2016	0.0×	—

Period	P/B ratio	Change
Sep 2026	3.9×	12.09%
Jun 2026	3.5×	(11.44%)
Mar 2026	4.0×	(11.29%)
Dec 2025	4.5×	(20.41%)
42 more quarters	Free account

Against its own ten years

Low 0.0× High 18.4×

Ten-year median 2.6×

Current reading's percentile 91

Company	P/B ratio
TLX Telix Pharmaceuticals Limited compare	n/m
CELC Celcuity, Inc. compare	n/m
IDYA IDEAYA Biosciences, Inc. compare	2.9×
ELVN Enliven Therapeutics, Inc. compare	3.3×
DNLI Denali Therapeutics Inc. compare	4.0×
DYN Dyne Therapeutics, Inc. compare	4.1×
VKTX Viking Therapeutics, Inc. compare	5.2×
VRDN Viridian Therapeutics, Inc.	5.5×
TARS Tarsus Pharmaceuticals, Inc. compare	30.1×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Viridian Therapeutics, Inc. (VRDN) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on VRDN

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on VRDN

Stockrow Weekly